Dr. Del Rosso discusses treatment escalation for patients whose moderate-to-severe plaque psoriasis remains inadequately controlled with topical or conventional systemic therapies or who experience treatment-limiting adverse events. The discussion highlights the role of interleukin (IL)-17 inhibition and explains how bimekizumab targets both IL-17A and IL-17F, providing broader pathway inhibition than agents that target IL-17A alone. Dr. Del Rosso reviews head-to-head data from several clinical trials, including comparative efficacy against other biologics. He also addresses candidiasis as an important safety consideration with dual IL-17A and IL-17F inhibition and discusses its typical management in clinical practice.
Topics Covered:
- Escalating patients with moderate-to-severe plaque psoriasis to biologic therapy
- Dual IL-17A and IL-17F inhibition and head-to-head efficacy data
- Candidiasis risk and practical safety considerations with bimekizumab
